Professor Thomas Tötterman, Clinical Immunology Division, Department of Immunology, Genetics & Pathology, Uppsala University, is an internationally recognized pioneer in the field of cancer immunotherapy. Alligator Bioscience has an extensive scientific collaboration with Professor Tötterman and his group that has led to the development of the IMCAN (IMmunotherapy of CANcer) concept for local immunotherapy of cancer. The Alligator pipeline has two projects within the IMCAN concept, ADC-1013 and ADC-1014, and Professor Tötterman is now involved in the pre-clinical development of these two projects. Thomas Tötterman received his MD from the University of Helsinki, 1975 and his PhD from the same University 1978. He was appointed Professor/Senior Consultant in Clinical Immunology 1995 and was President for the Swedish Society of Gene and Cell Therapy (SSGCT) 2006-2010. Thomas Tötterman has been Initiator/Sponsor of two academic phase I/II trials, “first-in-man”, studies with immunomodulatory drug candidates. He has published more than 170 peer-reviewed scientific papers including several reviews.
Professor David Erlinge, Dept. of Cardiology, Lund University, is internationally recognized within
the field of ischemia reperfusion injury after acute myocardial infarction. This is the primary indication for
ADC-1004, the furthermost advanced compound in the Alligator pipeline. The collaboration with Professor
Erlinge´s group has resulted in a highly successful Proof of Concept evaluation of ADC-1004 in human-
sized pigs. Professor Erlinge is now involved in the planned clinical development of ADC-1004.
David Erlinge received an MD from Lund University, Sweden 1990 followed by a PhD from the same
university. Professor Erlinge has been a visiting research fellow at Cornell University Medical College,
New York, NY. The clinical speciality is invasive cardiology (PCI). In 2006 Professor Erlinge received the
The Lars Werkö distinguished research fellowship and in 2008 Professor Erlinge was appointed Professor
in Cardiology at Lund University. The research is focused on acute coronary syndromes, platelet function
and cardioprotection. Professor Erlinge has published more than 110 original articles.